建新股份 reported revenue of ¥0.36B for the period ended 2026-06-30, +51.4% year on year. Net income was ¥0.05B, a 13.3% net margin on a 24.0% gross margin. The largest revenue line is 纸张化学品 at 37% of the total. Free cash flow for the period was ¥0.00B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.36B | +51.4% |
| Gross profit | ¥0.09B | — |
| Operating income | ¥0.05B | — |
| Net income | ¥0.05B | +790.3% |
| Gross margin | 24.0% | Net margin 13.3% |
| Revenue Q/Q | +37.0% | — |
| Segment | Revenue | Share |
|---|---|---|
| 纸张化学品 | ¥0.13B | 37.2% |
| 复合材料和新材料中间体 | ¥0.10B | 27.1% |
| 染料和日化中间体 | ¥0.08B | 22.5% |
| 医药和农药中间体 | ¥0.05B | 12.8% |
| 其他 | ¥0.00B | 0.4% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.27B | 76.0% |
| R&D | ¥0.02B | 4.6% |
| SG&A | ¥0.01B | 2.8% |
| Tax & other | ¥0.01B | 2.0% |
| Item | Amount |
|---|---|
| Total assets | ¥1.72B |
| Total liabilities | ¥0.20B |
| Shareholders' equity | ¥1.52B |
| Equity / assets | 88.5% |
| Operating cash flow | ¥0.04B |
| Capital expenditure | ¥0.04B |
| Free cash flow | ¥0.00B |
| Cash conversion (OCF / net income) | 53% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
新开源 ・ 华仁药业 ・ 向日葵 ・ 万讯自控 ・ 顺网科技 ・ 长盈精密 ・ 东方日升 ・ 瑞普生物 ・ 经纬辉开 ・ 阳谷华泰 ・ ST亚光 ・ 聆达股份
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies